Home
Live Updates
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Higher risk of mortality in previously hospitalized patients : comparemela.com
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Higher risk of mortality in previously hospitalized patients
Higher Risk of Mortality in Previously Hospitalized Patients: Insights From ATTRibute-CM
Ahmad Masri1, Michele Emdin2, Keyur Shah3, Kunal Bhatt4,...
Related Keywords
Australia ,
Portland ,
Oregon ,
United States ,
Dallas ,
Texas ,
Brisbane ,
Queensland ,
San Francisco ,
California ,
Palo Alto ,
Perth ,
Western Australia ,
Stanford University ,
Italy ,
Dariusz Korczyk ,
Kunal Bhatt ,
Michel Khouri ,
Kevin Alexander ,
Jonathanc Fox ,
Noel Dasgupta ,
Ahmad Masri ,
Michele Emdin ,
Martha Grogan ,
Michael Johnstone ,
Suresh Siddhanti ,
Olakunle Akinboboye ,
Fondazioneg Monasterio ,
Mazen Hanna ,
Leonid Katz ,
Keyur Shah ,
,
Astrazeneca ,
University Of Pittsburgh Medical Center ,
Syneos Health Medical Communications ,
Steward Health Care ,
Pfizer ,
Bridgebio Pharma Inc ,
Janssen Pharmaceuticals ,
Virginia Commonwealth University Health ,
Stanford University School Of Medicine ,
Shweta Bio Pharma Inc ,
Indiana University School Of Medicine ,
Duke Health ,
Bio Pharma Inc ,
Novo Nordisk ,
York Heart Association ,
Oregon Health Science University ,
Higher Risk ,
Previously Hospitalized Patients ,
Insights From ,
Kaitlyn Lam ,
Prem Soman ,
Science University ,
Commonwealth University Health ,
Health Care ,
University School ,
Barbara Zucker School ,
Alexandra Hospital ,
Australia Advanced Heart Failure ,
Cardiac Transplant Service ,
Pittsburgh Medical Center ,
Bio Pharma ,
Baseline Characteristics ,
Meier Curve ,
Cumulative Events ,
Bridgebio Pharma ,
New York Heart Association ,
Shweta Rane ,
comparemela.com © 2020. All Rights Reserved.